Literature DB >> 12496219

Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn.

R Gottstein1, R W I Cooke.   

Abstract

OBJECTIVES: To assess the effectiveness of high dose intravenous immunoglobulin (HDIVIG) in reducing the need for exchange transfusion in neonates with proven haemolytic disease due to Rh and/or ABO incompatibility. To assess the effectiveness of HDIVIG in reducing the duration of phototherapy and hospital stay.
DESIGN: Systematic review of randomised and quasi-randomised controlled trials comparing HDIVIG and phototherapy with phototherapy alone in neonates with Rh and/or ABO incompatibility.
RESULTS: Significantly fewer infants required exchange transfusion in the HDIVIG group (relative risk (RR) 0.28 (95% confidence interval (CI) 0.17 to 0.47); number needed to treat 2.7 (95% CI 2.0 to 3.8)). Also hospital stay and duration of phototherapy were significantly reduced.
CONCLUSION: HDIVIG is an effective treatment.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12496219      PMCID： PMC1755998          DOI： 10.1136/fn.88.1.f6

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN： 1359-2998            Impact factor:   5.747


  23 in total

1.  Management of severe alloimmune thrombocytopenia in the newborn.

Authors:  W H Ouwehand; G Smith; E Ranasinghe
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-05       Impact factor: 5.747

2.  ADCC (K-cell) lysis of human erythrocytes sensitized with rhesus alloantibodies. II. Investigation into the mechanism of lysis.

Authors:  S J Urbaniak
Journal:  Br J Haematol       Date:  1979-06       Impact factor: 6.998

3.  Consequences for fetus and neonate of maternal red cell allo-immunisation.

Authors:  H Howard; V Martlew; I McFadyen; C Clarke; J Duguid; I Bromilow; J Eggington
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-01       Impact factor: 5.747

4.  Classical Kawasaki disease in a neonate.

Authors:  T V Stanley; K Grimwood
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-03       Impact factor: 5.747

5.  Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA.

Authors:  A W Burks; H A Sampson; R H Buckley
Journal:  N Engl J Med       Date:  1986-02-27       Impact factor: 91.245

6.  Morbidity and mortality associated with exchange transfusion.

Authors:  W J Keenan; K K Novak; J M Sutherland; D A Bryla; K L Fetterly
Journal:  Pediatrics       Date:  1985-02       Impact factor: 7.124

7.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

8.  High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice.

Authors:  F Alpay; S U Sarici; V Okutan; G Erdem; O Ozcan; E Gökçay
Journal:  Acta Paediatr       Date:  1999-02       Impact factor: 2.299

9.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

10.  Idiopathic thrombocytopenic purpura in pregnancy and neonatal period.

Authors:  G Wenske; G Gaedicke; H Heyes
Journal:  Blut       Date:  1984-06
View more
  27 in total

1.  Blood transfusion.

Authors:  P H B Bolton-Maggs; M F Murphy
Journal:  Arch Dis Child       Date:  2004-01       Impact factor: 3.791

Review 2.  Neonatal transfusion practice.

Authors:  N A Murray; I A G Roberts
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-03       Impact factor: 5.747

3.  Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn--a prospective randomized controlled trial.

Authors:  Mohsen Saleh Elalfy; Nancy Samir Elbarbary; Heba Wegdan Abaza
Journal:  Eur J Pediatr       Date:  2010-10-06       Impact factor: 3.183

Review 4.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

Review 5.  Haemolytic disease of the newborn.

Authors:  Neil A Murray; Irene A G Roberts
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2007-03       Impact factor: 5.747

6.  Addressing hemolysis in an infant due to mother-infant ABO blood incompatibility.

Authors:  Sandra Martin; Rebecca N Jerome; Marcia I Epelbaum; Annette M Williams; William Walsh
Journal:  J Med Libr Assoc       Date:  2008-07

7.  Improving the management and outcome in haemolytic disease of the foetus and newborn.

Authors:  Enrico Lopriore; Mirjam E A Rath; Helen Liley; Vivianne E H J Smits-Wintjens
Journal:  Blood Transfus       Date:  2013-07-19       Impact factor: 3.443

8.  Intravenous immunoglobulin in pediatrics: A review.

Authors:  A N Prasad; Sanjay Chaudhary
Journal:  Med J Armed Forces India       Date:  2013-08-06

9.  Intravenous Immunoglobulin G Treatment in ABO Hemolytic Disease of the Newborn, is it Myth or Real?

Authors:  Serdar Beken; Ibrahim Hirfanoglu; Canan Turkyilmaz; Nilgun Altuntas; Sezin Unal; Ozden Turan; Esra Onal; Ebru Ergenekon; Esin Koc; Yildiz Atalay
Journal:  Indian J Hematol Blood Transfus       Date:  2012-08-28       Impact factor: 0.900

10.  Anti-Ge3 causes late-onset hemolytic disease of the newborn: the fourth case in three Hispanic families.

Authors:  Lisa Lee Pate; Jessica C Myers; Jonathan P Palma; Maurene Viele; Susan A Galel; Zenaida Ferrer; Christopher L Gonzalez; William E Benitz; George Garratty; Magali J Fontaine
Journal:  Transfusion       Date:  2012-12-12       Impact factor: 3.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.